On this page
Besponsa
inotuzumab ozogamicin
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Besponsa
Proper name
inotuzumab ozogamicin
Licence type
351(a)
BLA number
761040
Applicant
Wyeth Pharmaceuticals LLC
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 0.9MG | For Injection | Intravenous | Single-Dose Vial | Rx | August 17, 2017 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | March 6, 1931 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |